New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
New KDIGO guidelines since 2021, Lupus Nephritis is seeing lots of new therapeutics in the pipeline.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) February 9, 2024
✳️10 tweets #NephJC catch-up ✳️
✴️Let’s recap the 2024 KDIGO Lupus Nephritis Guidelines!@BradRovin @AyuobIsabelle @meg21212 @cellotonelli @Gordon7Craig#KDIGO2024
❣️Didn’t get to join the 🐺pack for this one, no worries we’ll help you wolf it down 🥩! pic.twitter.com/Xg8NdWdH23